A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial

To evaluate the efficacy and toxicity of a brief, intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for patients with stage IIIB and IV non-small cell lung cancer (NSCLC) and a favorable performance status. Thirty patients with no prior chemother...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 1998-12, Vol.22 (3), p.227-234
Main Authors: Levitan, Nathan, Dowlati, Afshin, Craffey, Mark, Tahsildar, Hassan, MacKay, Wilma, McKenney, John, Remick, Scot C.
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - mortality
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Appetite Stimulants - therapeutic use
Biological and medical sciences
Carcinoma, Adenosquamous - drug therapy
Carcinoma, Adenosquamous - mortality
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - mortality
Chemotherapy
Cisplatin - administration & dosage
Clinical trial
Drug Administration Schedule
Etoposide - administration & dosage
Female
Filgrastim
Granulocyte Colony-Stimulating Factor - therapeutic use
Humans
Ifosfamide - administration & dosage
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Male
Medical sciences
Megestrol Acetate - therapeutic use
Mesna - administration & dosage
Middle Aged
Non-small cell lung cancer
Pharmacology. Drug treatments
Protective Agents - administration & dosage
Recombinant Proteins
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the efficacy and toxicity of a brief, intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for patients with stage IIIB and IV non-small cell lung cancer (NSCLC) and a favorable performance status. Thirty patients with no prior chemotherapy were enrolled in this phase II protocol. Patients received cisplatin 50 mg/m2, ifosfamide 2 g/m2, mesna, and a 7-day course of oral etoposide beginning on days 1, 15, 29, 43, and 57 for a total treatment duration of 10 weeks. Filgrastim was administered for 7 days after each course of oral etoposide. Megestrol acetate 250 mg PO was administered throughout the duration of chemotherapy. Thirty patients were evaluable for toxicity and 27 for response. Among those evaluable for response, partial remission occurred in 11 (41%) patients, and median survival was 10.5 months. Nadir neutrophil count of
ISSN:0169-5002
1872-8332
DOI:10.1016/S0169-5002(98)00087-7